FINWIRES · TerminalLIVE
FINWIRES

調査速報:ハンティントン・インガルス、第1四半期決算発表:売上高の伸びは利益率の低下によって相殺される

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。HIIは第1四半期の売上高が前年同期比13.4%増の31億ドルとなり、市場予想を2.7%上回りました。しかし、売上高の増加にもかかわらず、営業利益率は89ベーシスポイント低下し、5.0%となりました。第1四半期の1株当たり利益(EPS)は3.79ドルで、前年同期と同水準、市場予想を0.08ドル上回りました。今回の結果は、当社が注視してきた課題を浮き彫りにしています。売上高の伸びは良好な需要環境を裏付けるものですが、造船事業の利益率目標である9~10%の達成は、予想よりも緩やかなものとなっています。経営陣は、2026年度の造船事業の売上高を97~99億ドル、営業利益率を5.5~6.5%、フリーキャッシュフローを5億~6億ドルとするガイダンスを再確認しました。ニューポートニューズ事業は、売上高が19.3%増の17億ドルとなり成長を牽引しましたが、バージニア級契約の有利な調整がなかったため、セグメント利益率は80ベーシスポイント低下し5.3%となりました。フリーキャッシュフローは4億6100万ドルのマイナスとなりました。当社は、現在進行中のバージニア・ブロックVIおよびコロンビア・ビルドIIの契約締結が、現在のコスト構造を反映し、将来の事業における利益率向上につながるため、引き続き重要な起爆剤になると考えています。

Related Articles

Commodities

Avista Q1 Energy Volumes Drop Across Segments Amid Softer Demand

Avista (AVA) reported Q1 earnings Tuesday, with electricity and natural gas volumes declining as milder weather reduced demand, with residential usage down 10% and commercial down 6%.The company reported total residential electricity sales through its operating unit, Avista Utilities, at 1.15 gigawatt-hours, down from 1.27 GWh a year earlier.Electricity sales to the commercial sector were 768 megawatt-hours for the quarter ended March 31, compared with 808 MWh a year earlier.The company reported industrial electricity sales for 455 MWh for the quarter, down from 469 MWh a year earlier, while wholesale sales were 912 MWh, down from 951 MWh a year earlier.The company reported total residential natural gas sales through its operating unit, Avista Utilities, of 8,490.7 billion British thermal units delivered, down from 9,888.1 billion Btu delivered a year earlier.Commercial natural gas sales were 5,116.1 billion Btu delivered for the quarter ended March 31, compared with 5,961.9 billion Btu delivered a year earlier.The company reported wholesale natural gas volumes of 5,446.1 billion Btu delivered in Q1, down from 6,752.8 billion Btu delivered a year earlier.Other natural gas volumes were 5,446.1 billion Btu delivered for the quarter, compared with 5,401.9 billion Btu delivered a year earlier.Avista is also advancing a new enterprise resource planning system targeted for completion in 2028, with estimated capital expenditures of about $130 million to enhance operational efficiency and financial reporting capabilities.Price: $40.81, Change: $+0.25, Percent Change: +0.62%

$AVA
Australia

Primo Brands' Q1 Faces Pressure From Service Disruptions, Cost Headwinds, RBC Says

Primo Brands (PRMB) is expected to face pressure in Q1 from extended service disruptions tied to winter storms and higher input costs linked to the Middle East conflict, RBC Capital Markets said in a note emailed Tuesday.The firm said Q1 is likely to be the weakest quarter of the year and could be further affected by lost or unrecoverable delivery sales from the winter storms.Retail business trends appear supportive, with sales growth of 6% in scanner data, RBC said, adding that the company has taken pricing on about 15% of its retail volume outside its core case pack business.Primo Brands also remains highly sensitive to petroleum-linked costs, including resin, glass, aluminum and diesel fuel, though it has significant hedge coverage in place for 2026 and levers such as pricing and fuel surcharges, the note said.Primo Brands is expected to report Q1 financial results on Thursday.RBC maintained its outperform rating on Primo Brands and kept its price target at $28.Price: $20.37, Change: $+0.27, Percent Change: +1.37%

$PRMB
Australia

BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is entering a "transition year" in 2026, prioritizing growth acceleration and market share gains as its expanded enzyme portfolio scales following the acquisition of Amicus Therapeutics (FOLD), Morgan Stanley said in a report Tuesday.In its Q1 results, BioMarin raised its fiscal 2026 revenue guidance to $3.825 billion to $3.925 billion, driven by contributions from newly added therapies Galafold and Pombiliti plus Opfolda, but lowered its non-GAAP earnings per share outlook to $4.85 to $5.05 due to integration-related costs and higher interest expenses, associated with the transaction, the report said.BioMarin is focused on scaling its expanded enzyme portfolio and driving commercial execution, with its management expected to outline a detailed roadmap in Q2 covering "long-term revenue potential," peak sales and cost synergies, the investment bank said.Earnings are expected to be weighted toward the second half of 2026, with the Amicus deal seen by the management as "slightly dilutive" this year but "accretive" within 12 months and more meaningful in start of 2027, the report said.The "combined enzyme portfolio" is expected to support durable growth and help offset rising competition for Voxzogo, while pipeline developments and new launches, including Palynziq expansion and BMN-333, could further support long-term growth, according to the report.Morgan Stanley has an overweight rating on BioMarin Pharmaceutical and lowered its price target to $119 from $120.Price: $54.26, Change: $-1.20, Percent Change: -2.16%

$BMRN$FOLD